CA2109435A1 - Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre - Google Patents

Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre

Info

Publication number
CA2109435A1
CA2109435A1 CA2109435A CA2109435A CA2109435A1 CA 2109435 A1 CA2109435 A1 CA 2109435A1 CA 2109435 A CA2109435 A CA 2109435A CA 2109435 A CA2109435 A CA 2109435A CA 2109435 A1 CA2109435 A1 CA 2109435A1
Authority
CA
Canada
Prior art keywords
compositions
methods
broad spectrum
phosphonoacetyl
aspartic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2109435A
Other languages
English (en)
Other versions
CA2109435C (fr
Inventor
Herbert A. Blough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/032,234 external-priority patent/US5491135A/en
Application filed by Individual filed Critical Individual
Publication of CA2109435A1 publication Critical patent/CA2109435A1/fr
Application granted granted Critical
Publication of CA2109435C publication Critical patent/CA2109435C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002109435A 1992-03-18 1993-03-18 Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre Expired - Fee Related CA2109435C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85345492A 1992-03-18 1992-03-18
US853,454 1992-03-18
US08/032,234 US5491135A (en) 1992-03-18 1993-03-17 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
US032,234 1993-03-17

Publications (2)

Publication Number Publication Date
CA2109435A1 true CA2109435A1 (fr) 1993-09-19
CA2109435C CA2109435C (fr) 1997-03-11

Family

ID=26708159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109435A Expired - Fee Related CA2109435C (fr) 1992-03-18 1993-03-18 Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre

Country Status (10)

Country Link
EP (1) EP0660710A1 (fr)
JP (1) JPH07507770A (fr)
CN (1) CN1080853A (fr)
AU (1) AU3965993A (fr)
BR (1) BR9306123A (fr)
CA (1) CA2109435C (fr)
IL (1) IL105090A (fr)
IS (1) IS3987A (fr)
MX (1) MX9301527A (fr)
WO (1) WO1993018763A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
EA004705B1 (ru) 1998-02-12 2004-06-24 Дж.Д.Серл Энд Ко. Применение n-замещенных 1,5-дидезокси-1,5-имино-d-глюцитных производных для лечения инфекций, вызываемых вирусами гепатита
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6515028B1 (en) 1999-02-12 2003-02-04 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
DE10343365A1 (de) * 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
CN111317733B (zh) * 2020-03-24 2022-07-12 中国人民解放军海军军医大学 利福霉素类抗生素在制备抗黄热病毒感染药物中的应用
WO2021189444A1 (fr) * 2020-03-24 2021-09-30 中国人民解放军海军军医大学 Utilisation d'antibiotiques du type rifamycine dans la préparation de médicaments contre des infections par le virus de la fièvre jaune
CN111419839A (zh) * 2020-03-31 2020-07-17 远见生物科技（上海）有限公司 利福霉素的新用途
WO2021221111A1 (fr) * 2020-04-30 2021-11-04 国立大学法人京都大学 Agent prophylactique ou thérapeutique pour des maladies liées au virus de l'arn
EP4313150A1 (fr) * 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Combinaison d'inhibiteur de la biosynthèse de la pyrimidine destinée à être utilisée dans le traitement d'infections virales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178306A (en) * 1978-08-10 1979-12-11 Parsons Jack L Preparation of N-(phosphonoacetyl)-L-aspartic acid

Also Published As

Publication number Publication date
IS3987A (is) 1993-09-19
CN1080853A (zh) 1994-01-19
AU3965993A (en) 1993-10-21
MX9301527A (es) 1994-02-28
IL105090A (en) 1998-08-16
WO1993018763A1 (fr) 1993-09-30
EP0660710A4 (fr) 1995-03-02
IL105090A0 (en) 1994-08-26
BR9306123A (pt) 1997-08-26
CA2109435C (fr) 1997-03-11
EP0660710A1 (fr) 1995-07-05
JPH07507770A (ja) 1995-08-31

Similar Documents

Publication Publication Date Title
CA2109435A1 (fr) Compositions d'acide n-(phosphonoacetyl)-l-aspartique et methodes pour leur utilisation comme agents antiviraux a large spectre
CA2152486A1 (fr) Sulfamates de sorbopyranose, anticonvulsifs
IE45256L (en) Quinazolone derivatives
AU3132489A (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
TW288011B (fr)
CA2143636A1 (fr) Derives d'amides de l'acide valproique et l'acide valpro-2-enoique et leur utilisation en tant qu'anticonvulsivants
CA2129288A1 (fr) Esters phosphonooxymethyliques de derives de taxane
CA2259621A1 (fr) Derives d'isocoumarine et utilisation de ces derniers dans des medicaments
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
IL86381A0 (en) Oxetanocins and pharmaceutical compositions containing the same
HUT61780A (en) Process for producing new peptides and pharmaceutical compositions comprising same as active ingredient
GB9601202D0 (en) Piperidones
CA2100655A1 (fr) Nucleosides oxypuriniques, leurs congeneres et leurs derives acyles utilises dans la stimulation de l'hematopoiese
CA2098020A1 (fr) Composes antiviraux
CA2140927A1 (fr) Inhibiteurs d'agregation plaquettaire
AP9300561A0 (en) Antibiotic compounds.
MY105538A (en) Derivatives of thieno-triazolo-diazepine, a preparation process of the same and therapeutic compositions containing them.
ES8504682A1 (es) Un procedimiento para la preparacion de compuestos nitro alifaticos
CA2020474A1 (fr) Compose anti-inflammatoire ou antiallergique
GR3007401T3 (fr)
IE832273L (en) 7-substituted-3-vinyl-3-cephem compounds
EP0546177A4 (fr) Derive de benzopyrane, sa production, et composition pharmaceutique le contenant.
HK1023346A1 (en) Novel substituted tetrahyropyridine derivatives, method of preparation and pharmaceutical compositions containing them
CA2025858A1 (fr) Compose antihepatopathique
IE893258L (en) New 2-carbonyl substituted n,n'-di-(trimethoxybenzoyl)¹piperazines, process for preparing the same and¹therapeutical compounds containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20000320